MedTrace Logo

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

NCT05067478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403

Last updated 2024-12-27

No results posted yet for this study

Summary

This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.

Conditions

Interventions

DRUG

Vibegron

Vibegron to be administered.

Sponsors & Collaborators

  • Urovant Sciences GmbH

    lead INDUSTRY

Principal Investigators

  • Study Director · Urovant Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2024-07-22
Completion
2024-07-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067478 on ClinicalTrials.gov